Well-characterized cancer targets such as mutant EGFR in non-small cell lung cancer (NSCLC) and the BCR-Abl fusion gene in chronic myelogenous leukemia (CML) led to initial breakthroughs,12,31,37 and success via this approach has continued to expand as more than 150 targeted therapeutics have been approved to date by the FDA to treat various cancer subtypes.48 Unfortunately, sustained therapeutic efficacy has been limited by the emergence of drug resistance. Here, EGFR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.